The Food and Drug Administration isaid it issued a “safe to proceed” letter to Revolution Medicines (RVMD), allowing the company to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib. The expanded access treatment protocol is for patients with previously treated metastatic pancreatic ductal adenocarcinoma.. The FDA received the expanded access request from Revolution Medicines on April 28 and signed it on April 30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Erasca price target raised to $9 from $2 at BofA
- Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
- Erasca sinks after Revolution Medicines alleges patent infringement
- Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target
- Buy Rating on RVMD Driven by Promising Pancreatic Cancer Data and Next‑Generation RAS Franchise Potential